Transparent molecular structure representation illustrating concepts in harnessing structural insights for drug discovery.

Harnessing Structural Insights in Drug Discovery

Webinar

On-Demand

Want to share this FREE webinar with a colleague?

Fill out the form below and we'll send your colleague an invitation to the "Harnessing Structural Insights in Drug Discovery" event.

Structural information is pivotal to drug discovery, and 3D insights are streamlining various processes. However, selecting the right proteins for analysis and leveraging cutting-edge techniques remain critical challenges.

This webinar explores how structural biology drives success in drug discovery projects. Dr. Jay Bertrand discusses how to select optimal proteins for analysis, shares the advantages of X-ray fragment screening and cryo-EM techniques and presents case studies highlighting practical applications.

Watch this webinar to discover:

How structural insights transform target validation and drug design
Techniques for selecting proteins for optimal structural analysis
Real-world applications of these techniques in obtaining compound-bound structures

The Role of Structural Insights in Drug Discovery Structural information plays a pivotal role in drug discovery, and access to 3D information can streamline many aspects across the value chain. Dr. Jay Bertrand, Vice President, Head of Global Structural Biology and Evotec's Princeton Site Head, discusses the evolution of structural support to drug discovery projects, and provides insight into choosing the right protein for structural analysis. He will also share case studies on the application of X-ray and cryo-EM to obtain compound-bound protein structures. Jay Bertrand VP Head of Global Structural Biology & Princeton Site Head Biography Dr Bertrand has a Ph.D. in biochemistry from Georgia Institute of Technology (1994) with a focus on protein crystallography. He then spent three years in Grenoble, France at the Institut de Biologie Structurale where he worked on a joint project with Roussel Uclaf on the antibacterial target MurD before returning to the US to work with Janet Smith at Purdue University. In 2000, Jay transferred from academia to industry with an initial role in Roche Palo Alto providing structural support to inflammation projects before moving on to Pharmacia in Milan, Italy to support oncology projects. While in Milan, Jay’s role evolved from a Principal Scientist to the Head of Structural Chemistry and, during the same time, ownership of the site changed from Pharmacia to Pfizer before eventually becoming Nerviano Medical Sciences. In 2012, he joined Vertex Pharmaceuticals Oxford, UK site as a Research Fellow and Director of Structural Biology and Biophysics. During his time in the UK, he implemented fragment screening techniques that delivered novel chemistry starting points to oncology projects and led the integration of Cryo-EM into the Vertex Oxford workflow. In 2021, he joined Evotec as VP Head of Global Structural Biology and, more recently, took on the role of Princeton Site Head. During his time in academia and industry, Jay has been named in 6 chemical patents and co-authored 32 publications, covering a broad range of targets and therapeutic areas. He’s also participated in teams delivering 11 clinical candidates of which 3 have become marketed drugs.

Speaker

Jay Bertrand, PhD

VP Head of Global Structural Biology & Princeton Site Head

Evotec

Dr Bertrand has a Ph.D. in biochemistry from Georgia Institute of Technology (1994) with a focus on protein crystallography. He then spent three years in Grenoble, France at the Institut de Biologie Structurale where he worked on a joint project with Roussel Uclaf on the antibacterial target MurD before returning to the US to work with Janet Smith at Purdue University. In 2000, Jay transferred from academia to industry with an initial role in Roche Palo Alto providing structural support to inflammation projects before moving on to Pharmacia in Milan, Italy to support oncology projects. While in Milan, Jay’s role evolved from a Principal Scientist to the Head of Structural Chemistry and, during the same time, ownership of the site changed from Pharmacia to Pfizer before eventually becoming Nerviano Medical Sciences. In 2012, he joined Vertex Pharmaceuticals Oxford, UK site as a Research Fellow and Director of Structural Biology and Biophysics. During his time in the UK, he implemented fragment screening techniques that delivered novel chemistry starting points to oncology projects and led the integration of Cryo-EM into the Vertex Oxford workflow. In 2021, he joined Evotec as VP Head of Global Structural Biology and, more recently, took on the role of Princeton Site Head. During his time in academia and industry, Jay has been named in 6 chemical patents and co-authored 32 publications, covering a broad range of targets and therapeutic areas. He’s also participated in teams delivering 11 clinical candidates of which 3 have become marketed drugs.

Learn about our editorial policies

VP Head of Global Structural Biology & Princeton Site Head

Evotec

Brought to you by

Have a question about our online events and webinars? Get in touch here.

Now Available on Demand!

Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.

Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar

Experiencing issues viewing the form? Click here to access an alternate version